🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

By reducing bottlenecks, streamlining their workflow, and increasing output, the NovaSeq X Plus is changing what is possible for Admera Health, LLC and allowing them to expand their services. Hear from their CEO, Yun Zhao, MD, on the progress they have made in just ten short years:

Can AI and data help make precision medicine more accessible? That’s the goal of our latest collaboration with Tempus. We’re working together to accelerate clinical insights and demonstrate the value of molecular profiling. Read more about our partnership here:

The work happening in labs today matters more than ever. Every test, every analysis, every question drives progress. This #LabWeek, we honor the experts whose precision shapes the future of science.

What’s next in #multiomics? CEO Jacob Thaysen sat down with Julianna LeMieux PhD, Deputy Editor-in-Chief at Genetic Engineering & Biotechnology News, to discuss how integrating omics data could transform our understanding of biology and accelerate drug discovery. Watch the full conversation: webinars.liebertpub.com/e/the-state-of….

We’re marking DNA Day with a spotlight on the students who represent the future of science. From strawberry DNA extractions in U.S. classrooms to escape room-style experiments in Singapore, thousands of students are stepping into the world of genomics, many for the first time. 🧬

The Illumina Genomics Summit in Jakarta, cohosted with Pandu Biosains, convened local clinicians, researchers, and public health leaders to lay a vision for the future of health care in Indonesia. Together, they are working to build the path to precision medicine in the country

“Before, multiomics meant stitching together data from multiple labs, multiple methods. Now it’s all possible with NGS—making integration easier and more reproducible." At #AACR25, Fiona Kaper, VP and Head of Assay R&D at Illumina, laid out the new path forward. With Illumina

Roughly one in eight adults in the United States have used a glucagon-like peptide-1 (GLP-1) receptor agonist, but studies show that almost 40% do not respond effectively to treatment. We're launching a dataset to enable better understanding the molecular basis of GLP-1 therapy

For Sireesha Lujan, customer accessibility was a top priority for the MiSeq i100 Series. “We wanted anyone to be able to turn it on and start sequencing right away. That’s what we mean when we say, ‘Genomics for all.’ Everyone should have access.” Her team’s deep technical

🔬 The future of biology is multiomic.​ Our CTO, Steve Barnard, PhD, recently shared his vision for the next frontier in precision medicine. ​ Check out these key takeaways from Steve’s piece to understand how we’re making multiomics easier, more consistent, and more reliable.

DRAGEN v4.4 raises the bar again to make bioinformatics easier than ever. With major accuracy improvements and ready-to-run applications, researchers can get insights faster, no matter how complex the data. Discover what’s new in DRAGEN v4.4: bit.ly/4ddjz1Y

James Clarke, commercial lead for UK&I at Illumina, ran 250+ km through the Sahara in the Marathon des Sables—all to raise money for dementia patients. At Illumina, he brings that same drive to demonstrating how genomics can shape health care. Read how his passion fuels him—on

🌏 Building global connections to advance local impact. During a recent visit from the U.S. Embassy, we had the opportunity to showcase how Illumina is advancing the future of precision medicine through innovation, both in technology and in infrastructure. From the Singapore

Brain tumors are extremely tough to classify and diagnose. One of New York's top experts, Dr. Matija Snuderl, is reshaping brain cancer diagnostics with DNA methylation profiling—a technique that’s changing lives by reducing misdiagnoses and guiding patients to the right

Couldn’t attend #ESHG2025? We hosted two sessions—from multiomics with leaders like Genomics England & Broad Institute to rapid newborn screening powered by the Illumina Constellation mapped read technology. 🎥 Watch the full recap: bit.ly/4keyPyr

Later this week, we will be joined by researchers, clinicians, and patient advocates to drive the future of cancer care at #ASCO25. We continue to expand our clinical oncology portfolio, providing clinicians with a suite of tumor profiling solutions that we will feature for the

In a study presented at #ASCO25, researchers at Frederick National Laboratory for Cancer Research’s Molecular Characterization (MoCha) Laboratory and Illumina collaborators studied approximately 2,000 banked blood samples from the NCI-MATCH trial. Together, they demonstrated that

Every year, 20 million patients face a cancer diagnosis. At Illumina, we believe they deserve more than promising research—they deserve access to breakthroughs in precision oncology. As the oncology community gathers at #ASCO25, our CEO Jacob Thaysen, PhD, shares why now is the